Scopus BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	4.08	9.03	12.61	2.73	2.23	0.41
Research & Development	5.27	2.68	15.02	7.42	0.46	0.28
Operating Expenses	9.34	11.71	27.63	10.16	2.69	0.69
Operating Income	-2,622.97	-11.71	-27.63	-10.16	-2.69	-0.69
Interest Expense	0	0	0.77	0.71	0	0
Other Expense / Income	-5,227.25	-	-1.46	-	-	-
Pretax Income	-9.34	-11.71	-26.95	-10.86	-2.69	-0.69
Income Tax	2,613	-0.11	0.77	0.71	0	0
Net Income	-8.7	-11.61	-27.73	-11.57	-2.69	-0.69
Shares Outstanding (Basic)	40	21	17	13	15	15
Shares Outstanding (Diluted)	40	21	17	13	15	15
Shares Change	88.40%	22.27%	29.11%	-10.77%	-	-
EPS (Basic)	-0.32	-0.55	-1.61	-0.87	-0.18	-0.05
EPS (Diluted)	-0.32	-0.55	-1.61	-0.87	-0.18	-0.05
Free Cash Flow	-4.59	-8.13	-11.43	-2.53	-2.12	-0.75
Free Cash Flow Per Share	-0.12	-0.39	-0.66	-0.19	-0.14	-0.05
EBITDA	-9.34	-11.71	-27.63	-10.15	-2.69	-0.69
Depreciation & Amortization	0	0	0	0	0	0
EBIT	-9.34	-11.71	-27.63	-10.16	-2.69	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.